Demand for prophylaxis after bioterrorism-related anthrax cases, 2001

Emerging Infectious Diseases

Volumn 11, Issue 1, 2005, Pages 42-47

  Belongia, Edward A ^a   Kieke, Burney ^a   Lynfield, Ruth ^b   Davis, Jeffrey P ^c   Besser, Richard E ^d  

^a MARSHFIELD CLINIC   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

^c WISCONSIN DIVISION OF PUBLIC HEALTH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; BIOLOGICAL WARFARE; CLINICAL PRACTICE; DRUG USE; HUMAN; OUTPATIENT CARE; PRESCRIPTION; REGRESSION ANALYSIS; REVIEW; UNITED STATES;

EID: 11844271984     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1101.040272     Document Type: Review

References (18)

1. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019-28.
2. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep. 2001;50:973-6.
3. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124-32.
4. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-82.
5. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related inhalational anthrax-Connecticut, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1049-51.
6. ABC News/The Washington Post. ABC News/Washington Post anthrax poll, October 2001, ICPSR version. Ann Arbor (MI): Inter-university Consortium for Political and Social Research; 2001.
7. Cowley G. A run on antibiotics. Newsweek. 2001;138(17):36.
8. Kinsley M. Be a patriot. Don't hoard Cipro! Time. 2001 Oct. 29:73.
9. Tsai AC, Lurie P, Sehgal AR. An outbreak of web sites selling ciprofloxacin following an outbreak of anthrax by mail. Am J Med. 2002;113:424-7.
10. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-99. MMWR Morb Mortal Wkly Rep. 2001;50:800-4.
11. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-50.
12. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-8.
13. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneu-moniae: a case-control study. Clin Infect Dis. 2001;32:701-7.
14. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-19.
15. Brinker A, Pamer C, Beitz J. Changes in ciprofloxacin utilization as shown in a large pharmacy claims database: effects of proximity to criminal anthrax exposure in October 2001. J Am Pharm Assoc. 2003;43:375-8.
16. Shaffer D, Armstrong G, Higgins K, Honig P, Coyne P, Boxwell D, et al. Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign. Pharmacoepidemiol Drug Saf. 2003;12:177-82.
17. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719-25.
18. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000;133:128-35.